GlaxoSmithKline posted an 11% jump in first quarter profit boosted by its consumer healthcare unit with brands such as Lucozade and Macleans and from its worldwide pharmaceutical business.
The healthcare giant said pre-tax profit rose to £1.8bn from £1.6bn last year on turnover which climbed 2% to £5.2bn for the first quarter to March 31.
Sales of nutritional healthcare products grew 2% to £135m driven by a 7% rise in Lucozade sales. Oral care sales also rose 2% to £252m with a 5% fall in Aquafresh tooothpaste sales offset by growth from Macleans, Sensodyne, Polident and Corega.
Over-the-counter medicine sales were up 10% to £369m while asthma drug Advair produced sales of £514m in the period making it GSK’s number one product.
Chief executive officer Jean-Pierre Garnier said: “GSK continues to deliver extremely solid financial performance based on a strong and broad portfolio of products.
“At the same time, effective cost control is continuing to improve profitability.”
The healthcare giant said pre-tax profit rose to £1.8bn from £1.6bn last year on turnover which climbed 2% to £5.2bn for the first quarter to March 31.
Sales of nutritional healthcare products grew 2% to £135m driven by a 7% rise in Lucozade sales. Oral care sales also rose 2% to £252m with a 5% fall in Aquafresh tooothpaste sales offset by growth from Macleans, Sensodyne, Polident and Corega.
Over-the-counter medicine sales were up 10% to £369m while asthma drug Advair produced sales of £514m in the period making it GSK’s number one product.
Chief executive officer Jean-Pierre Garnier said: “GSK continues to deliver extremely solid financial performance based on a strong and broad portfolio of products.
“At the same time, effective cost control is continuing to improve profitability.”
No comments yet